Treatment of the patient with primary familial heterozygous hypercholesterolemia.
Familial heterozygous hypercholesterolemia (FH) is a genetically linked lipid disorder that involves elevations in total cholesterol and LDL cholesterol. About 5% of patients with coronary heart disease have FH. Treatment options include dietary therapy, weight optimization, exercise, and drug treatment. A case study of a patient who has undergone 4 years of treatment for FH after a diagnosis of coronary heart disease is presented. Nursing care was instrumental in the patient's compliance with and adherence to the treatment plan.
Avery
B R
BR
Lipid Institute, Sequoia Hospital, Redwood City, California, USA.
D000368:Aged; D003084:Colestipol / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications* / Q000451:nursing; D018752:Diet, Fat-Restricted; D004359:Drug Therapy, Combination; D015444:Exercise; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000451:nursing* / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008148:Lovastatin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use; D010349:Patient Compliance; D015431:Weight Loss
D000960:Hypolipidemic Agents; D009525:Niacin; D008148:Lovastatin; D003084:Colestipol